Table 1.

Selected clinical trials of m-TOR inhibitors + ET.

Study	Design	Drug combination	N	Results
Baselga et al.28	Phase II Neoadjuvant	Letrozole-everolimus	270	RR by clinical examination, 59.1% to 68.1%
TAMRAD30	Phase II MBC pretreated	Tamoxifen-everolimus vs tamoxifen	111	TTP increased from 4.5 to 8.6 m
HORIZON29	Phase III MBC 1st line	Letrozole-temsirolimus vs letrozole	1112	No improvement in PFS 9 vs 8.9 m
BOLERO-231	Phase III MBC pretreated	Exemestane-everolimus vs exemestane	724	Increase in PFS from 4.1 to 10.6 m
BOLERO-432	Phase II MBC 1st line	Letrozole-everolimus vs letrozole	202	Median PFS not reached at 17.5 m
PrECOG 010233	Phase II MBC pretreated	Fulvestrant-everolimus vs fulvestrant	131	Increase in PFS 10.4 to 5.1 m

m, months; PFS, progression free survival; MBC, metastatic breast cancer: RR, response rate; TTR time to progression.